Claire Mazumdar Sells 10,000 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 10,000 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.98, for a total value of $279,800.00. Following the transaction, the chief executive officer directly owned 362,152 shares of the company’s stock, valued at $10,133,012.96. This represents a 2.69% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Claire Mazumdar also recently made the following trade(s):

• On Friday, July 10th, Claire Mazumdar sold 10,000 shares of Bicara Therapeutics stock. The stock was sold at an average price of $28.42, for a total transaction of $284,200.00.

Bicara Therapeutics Stock Up 3.7%

Bicara Therapeutics stock traded up $0.87 during midday trading on Wednesday, hitting $24.63. The company’s stock had a trading volume of 810,259 shares, compared to its average volume of 608,476. Bicara Therapeutics Inc. has a 12 month low of $10.30 and a 12 month high of $30.99. The company has a market capitalization of $1.62 billion, a PE ratio of -8.86 and a beta of -0.75. The stock’s 50-day moving average price is $25.90 and its 200-day moving average price is $21.69.

Bicara Therapeutics (NASDAQ:BCAX) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.82) earnings per share for the quarter, meeting the consensus estimate of ($0.82). As a group, equities analysts anticipate that Bicara Therapeutics Inc. will post -3.42 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the company. BTIG Research increased their price objective on Bicara Therapeutics from $28.00 to $39.00 and gave the company a “buy” rating in a research report on Wednesday. Morgan Stanley lifted their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the stock an “overweight” rating in a report on Tuesday. Wall Street Zen raised Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. Mizuho boosted their target price on Bicara Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bicara Therapeutics in a report on Wednesday, May 27th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Bicara Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $32.73.

Key Headlines Impacting Bicara Therapeutics

Here are the key news stories impacting Bicara Therapeutics this week:

• Positive Sentiment: Bicara reported a second-quarter loss of $0.82 per share, described as narrower than expected and matching the cited analyst consensus. The result helped support the view that the company is maintaining financial discipline while advancing its pipeline. Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results
• Positive Sentiment: The company said enrollment in its pivotal cancer study is progressing and remains on track for completion in 2026. Wedbush viewed the enrollment timeline as a positive catalyst for BCAX’s clinical program. Bicara Therapeutics’ Cancer Study On Track for 2026 Enrollment, Wedbush Says
• Positive Sentiment: BTIG Research raised its price target from $28 to $39 and maintained a Buy rating, implying substantial potential upside based on expectations for Bicara’s clinical and commercial prospects. Benzinga
• Positive Sentiment: Recent commentary remains constructive despite broader market headwinds, with optimism centered on the company’s pipeline progress and upcoming clinical milestones. Bicara Therapeutics: My Optimism Is Building Despite Recent Market Headwinds
• Neutral Sentiment: Bicara also announced strategic leadership transitions intended to support its next phase of execution and growth. The changes may improve operational focus, but they introduce an element of transition risk. Bicara Therapeutics Reports Second Quarter 2026 Progress
• Negative Sentiment: Wells Fargo raised its price target from $16 to $23 but retained an Equal Weight rating. Its target remains below the referenced trading level, signaling a more cautious view than BTIG’s forecast. Benzinga

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of BCAX. Candriam S.C.A. purchased a new stake in shares of Bicara Therapeutics in the first quarter worth approximately $4,750,000. UBS Group AG boosted its holdings in shares of Bicara Therapeutics by 97.4% during the fourth quarter. UBS Group AG now owns 192,191 shares of the company’s stock worth $3,235,000 after purchasing an additional 94,829 shares during the period. Janus Henderson Group PLC grew its position in Bicara Therapeutics by 26.2% during the first quarter. Janus Henderson Group PLC now owns 3,339,218 shares of the company’s stock valued at $66,350,000 after purchasing an additional 692,933 shares in the last quarter. Orbimed Advisors LLC grew its position in Bicara Therapeutics by 219.1% during the first quarter. Orbimed Advisors LLC now owns 667,300 shares of the company’s stock valued at $13,273,000 after purchasing an additional 458,200 shares in the last quarter. Finally, Siren L.L.C. increased its stake in Bicara Therapeutics by 11.2% in the 1st quarter. Siren L.L.C. now owns 5,802,970 shares of the company’s stock valued at $115,421,000 after buying an additional 586,001 shares during the period.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.